德国多发性硬化症患者长期处方药的成本模式
Michael Hecker1, Birgit Berger2, Niklas Frahm2
1Division of Neuroimmunology, Department of Neurology, Rostock University Medical Center, Rostock, Germany. michael.hecker@med.uni-rostock.de.
Scientific reports
|October 28, 2025
概括
多发性硬化症 (MS) 药物的年平均成本为11,788欧元,疾病修饰药物 (DMD) 占90%以上. 较年轻的多发性硬化症患者因早期的密集治疗而承担更高的药物成本.
科学领域:
- 神经学 神经学
- 卫生经济学 卫生经济学
背景情况:
- 多发性硬化症 (MS) 是一种慢性神经系统疾病,影响个人在他们的首要工作年.
- 多发性硬化症的治疗需要采用多模式的方法,这给患者,医疗保健系统和社会带来了巨大的财务负担.
- 药物处方是治疗多发性硬化症的主要直接成本之一.
研究的目的:
- 分析与多发性硬化症患者长期处方药物相关的成本.
- 确定年度药物费用与患者临床和人口特征之间的关系.
主要方法:
- 在德国三个医疗中心对728名多发性硬化患者的药物计划进行分析.
- 从LAUER-TAXE数据库 (2024年5月) 中利用药品定价数据.
- 单独计算疾病修饰药物 (DMD),症状治疗和并发症管理的成本.
主要成果:
- 每年平均每名患者的药物费用为11,788欧元.
- 疾病修饰药物 (DMD) 占药物总成本的92.1%.
- 在患有复发性多发性硬化和轻度至中度残疾的年轻患者中观察到更高的成本,这与更频繁使用昂贵的DMD有关.
- 症状和并发症药物的费用随着年龄,残疾和并发症数量的增加而增加.
结论:
- 处方药物是MS护理的实质性直接成本,患者之间的差异很大.
- 多发性硬化患者的临床异质性与药物消费和成本分布的多样性相关.
- 药物费用在50岁之前发生的最高,强调了早期,有效治疗的价值,以减轻长期间接成本.
相关概念视频
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
223
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
223
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
216
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
216
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
227
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
227
01:15Drug Dosing: Geriatric Patients
219
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
219
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
183
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
183
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
630
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
630